Navigation Links
Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
Date:5/12/2011

EAST NORRITON, Pa., May 12, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the three months ended March 31, 2011.

Neo-Urinary Conduit Bladder Cancer Trial – Clinical UpdateTengion is currently conducting an initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  This trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical technique for subsequent patients, as necessary.  To date, three patients have been enrolled and implanted in the clinical trial.  Clinical investigators have made surgical modifications in an effort to address conduit patency and vascular supply.  Based on clinical observations and complications to date, including events within the last week, the Company is extending its objective of reaching interim data in five patients into 2012.  The Company intends to provide an updated clinical timeline after a full assessment of the clinical data and plans for subsequent patient implants with investigators, the Data Safety Monitoring Committee and the FDA.

Neo-Kidney Augment Program UpdateTengion's lead preclinical program, the Neo-Kidney Augment, is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional kidney mass in patients with advanced chronic kidney disease (CKD).  Patients with end stage renal disease (ESRD) have CKD which has progressed to a point of little to no kidney function and these patients require dialysis or a kidney transplant to survive. According
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
10. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
11. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... Yale University, on March 27 released pre-clinical data on ... an oral presentation by Professor Gil Mor ... nd Annual Scientific Meeting of the Society of ... In both in vitro and in ...
(Date:3/30/2015)... March 30, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... No. 3:13-cv-03494-M and  Spherix v. Uniden , Case ... Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in ...
(Date:3/30/2015)... 2015 Richmond Pharmacology nimmt ... Pharmacology ist das erste Zentrum weltweit, das in ... Hospital in London in ... Studienversuche an einem Patienten begonnen hat. Das Therapeutikum ... entwickelt (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 ... the presentation of important study data showing ... cells in 1,599 gynecologic cancer samples. Using ... tumor profiling service, researchers identified expression of ... gynecologic cancers independent of histology while its ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
... DOYLESTOWN, Pa., June 12 The Quigley Corporation, (Nasdaq: ... , today announced the resignation of Guy J. ... The resignation is effective immediately, following a proxy contest which ... dissident shareholder Ted Karkus and his proposed slate of directors. ...
... ... Non-Invasive DNA Collection On-Site at Komen Western New York Race for the Cure® , ... Ottawa, ON (PRWEB) June 12, 2009 -- DNA ... partnered with the Roswell Park Cancer Institute (RPCI) to collect DNA saliva samples on-site ...
... crystalline form of carbon, whose extraordinary electron mobility and ... and photonics. But there,s a catch: graphene has no ... uses in electronics," says Feng Wang of the U.S. ... is a member of the Materials Sciences Division. "For ...
Cached Biology Technology:Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago 2Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago 3DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 3Bilayer graphene gets a bandgap 2Bilayer graphene gets a bandgap 3Bilayer graphene gets a bandgap 4
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Pa., Jan. 31, 2013   Shareholder rights attorneys ... BioClinica, Inc. (NASDAQ: BIOC ) by JLL ... biotechnology, and medical device companies. (Logo: ... 2013, BioClinica announced that it had entered into a ...
... medical technology leaders,Simon Fraser University and Fraser Health ... research and technology innovation with the launch of ... Leadership Chair in Multimodal Technology for Healthcare Innovation., ... Family Development, today announced the appointment of Simon ...
... especially in the coming years, when the International Energy ... renewable power. But what does science need to do ... Recently, three researchers discussed this with fellow scientist Harry ... Research Center on Light-Material Interactions in Solar Energy Conversion, ...
Cached Biology News:Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders' Best Interests 2Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders' Best Interests 3Leadership Chair to champion tech devices for brain trauma, disease 2Solar power: Is it time for the big push? 2
... Antibody Binding: High, 400 ng IgG/cm ... , Binding Interaction: Hydrophobic/Ionic , Performance Certified: ... Flat , Maximum Well Volume: 360 µl ... ,Features, Special optically clear polystyrene ...
... of Caspase/DIABLO Liquid. In 100 mM ... CYCLES. Amino acid residues 56 - 239 of ... sequence was expressed in and purified from ... with cytochrome c during apoptosis and ...
... JASCO offers a dedicated system for ... modular LC-1500 series of HPLC instrumentation. JASCO ... enhance the capability of the system: ,- ... chromatography and extraction procedures using carbon dioxide ...
... was originally formulated to support the growth ... gum moth,Antherea eucalypti. The medium is a ... resembleAnthereahemolymph. The cell lines established by Grace ... lines developed. The basal medium, when properly ...
Biology Products: